Candriam S.C.A. Lowers Stake in Moderna, Inc. $MRNA

Candriam S.C.A. reduced its position in Moderna, Inc. (NASDAQ:MRNA) by 21.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 220,986 shares of the company’s stock after selling 60,960 shares during the quarter. Candriam S.C.A.’s holdings in Moderna were worth $6,097,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Geode Capital Management LLC lifted its stake in shares of Moderna by 19.1% during the 2nd quarter. Geode Capital Management LLC now owns 8,877,280 shares of the company’s stock valued at $244,458,000 after buying an additional 1,420,690 shares in the last quarter. SHANDA ASSET MANAGEMENT HOLDINGS Ltd bought a new stake in Moderna during the first quarter valued at about $28,350,000. Jacobs Levy Equity Management Inc. purchased a new position in shares of Moderna in the first quarter valued at about $28,308,000. Jump Financial LLC boosted its stake in shares of Moderna by 5,590.0% in the first quarter. Jump Financial LLC now owns 902,427 shares of the company’s stock worth $25,584,000 after acquiring an additional 886,567 shares during the period. Finally, Invesco Ltd. grew its position in shares of Moderna by 17.5% during the first quarter. Invesco Ltd. now owns 5,883,624 shares of the company’s stock worth $166,801,000 after purchasing an additional 877,162 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors.

Moderna Stock Performance

Shares of MRNA opened at $24.77 on Friday. The stock has a market capitalization of $9.68 billion, a PE ratio of -3.07 and a beta of 2.02. The company’s fifty day moving average is $25.92 and its 200 day moving average is $27.08. Moderna, Inc. has a fifty-two week low of $23.04 and a fifty-two week high of $48.92.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.51) EPS for the quarter, beating the consensus estimate of ($2.15) by $1.64. Moderna had a negative net margin of 139.61% and a negative return on equity of 29.81%. The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $893.29 million. During the same quarter last year, the business earned $0.03 earnings per share. Moderna’s quarterly revenue was down 45.4% compared to the same quarter last year. Moderna has set its FY 2025 guidance at EPS. As a group, research analysts forecast that Moderna, Inc. will post -9.61 earnings per share for the current year.

Analyst Upgrades and Downgrades

MRNA has been the topic of a number of research analyst reports. Evercore ISI set a $32.00 price target on Moderna in a report on Friday, August 1st. Barclays lowered their target price on shares of Moderna from $31.00 to $25.00 and set an “equal weight” rating on the stock in a report on Friday, November 7th. Weiss Ratings restated a “sell (e+)” rating on shares of Moderna in a research report on Wednesday, October 8th. Bank of America reduced their price target on shares of Moderna from $24.00 to $21.00 and set an “underperform” rating on the stock in a report on Monday, November 10th. Finally, UBS Group decreased their price target on shares of Moderna from $70.00 to $40.00 and set a “buy” rating on the stock in a research note on Thursday, October 23rd. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, twelve have given a Hold rating and four have issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $35.85.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.